HEROXACIN

HEROXACIN (Ciprofloxacin 500 mg FC tablets ) Is a new fluoroquinolone antimicrobial agent with potent activity against a broad spectrum of gram-positive&gram-negative bacteria including Ps. acruginosa, Enterobacteriaceae and Staph aureus. Ciprofloxacin does not disturb normal anaerobic intestinal flora and, has significant post-antibiotic effect & thus prevents regrowth of bacteria. Its antibacterial spectrum is wider than that of aminoglycosides, third generation cephalosporins and other fluoroquinolones.

Category:

Description

Composition:

Ciprofloxacin 500 mg FC tablets.

Category:

Antibacterial.

Slogan:

HEROXACIN “The Antibacterial Hero

Summary:

HEROXACIN (Ciprofloxacin 500 mg FC tablets ) Is a new fluoroquinolone antimicrobial agent with potent activity against a broad spectrum of gram-positive&gram-negative bacteria including Ps. acruginosa, Enterobacteriaceae and Staph aureus. Ciprofloxacin does not disturb normal anaerobic intestinal flora and, has significant post-antibiotic effect & thus prevents regrowth of bacteria. Its antibacterial spectrum is wider than that of aminoglycosides, third generation cephalosporins and other fluoroquinolones.

HEROXACIN (Ciprofloxacin 500 mg FC tablets ) Is Characterized by:-

EXCELLENT EFFICACY:

Broad spectrum Bactericidal Covering G+VE, G-VE & Atypical 1st choice for typhoid fever & minimize the chance for relapse

Oral drug of choice for most sever & complicated infections

Used for the treatment of a wide range of infections

Ciprofloxacin is approximately 100 X potent than nalidixic a.

The most trusted FQ against P. aeruginosa

SUPERIOR PHARMACOKINETICS:

Superior Oral bioavailability & large volume of distribution

Quicker & longer duration of high plasma levels of the drug

Significant post-antibiotic effect prevents bacterial regrowth

Good intracellular penetration

Convenient dosage.

——————————————————————————————————————————————

Reviews

There are no reviews yet.

Be the first to review “HEROXACIN”

Your email address will not be published. Required fields are marked *